Noman Paracha

534 total citations
40 papers, 369 citations indexed

About

Noman Paracha is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Noman Paracha has authored 40 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 11 papers in Economics and Econometrics. Recurrent topics in Noman Paracha's work include Health Systems, Economic Evaluations, Quality of Life (8 papers), Economic and Financial Impacts of Cancer (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Noman Paracha is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (8 papers), Economic and Financial Impacts of Cancer (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Noman Paracha collaborates with scholars based in Switzerland, United States and United Kingdom. Noman Paracha's co-authors include Ahmed M. Abdulla Alabbasi, Federico Felizzi, Mark Sculpher, Andrew Davies, Alison Griffiths, Martín Cowie, Joshua Ray, C. Simone Sutherland, Pollyanna Hudson and Per-Olof Thuresson and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Urology.

In The Last Decade

Noman Paracha

35 papers receiving 369 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Noman Paracha Switzerland 12 132 105 104 55 53 40 369
Luc Ollivier France 9 109 0.8× 33 0.3× 115 1.1× 49 0.9× 39 0.7× 33 376
Diana Chirovsky United States 11 169 1.3× 36 0.3× 132 1.3× 77 1.4× 26 0.5× 43 461
Chloe J. Bright United Kingdom 10 205 1.6× 44 0.4× 84 0.8× 69 1.3× 14 0.3× 18 465
Yat Ming Lau China 7 142 1.1× 55 0.5× 89 0.9× 13 0.2× 13 0.2× 13 350
Laila A. Gharzai United States 10 56 0.4× 63 0.6× 96 0.9× 14 0.3× 20 0.4× 44 321
John Waller United Kingdom 10 107 0.8× 76 0.7× 102 1.0× 6 0.1× 115 2.2× 38 415
Kashyap Patel United States 10 56 0.4× 56 0.5× 33 0.3× 19 0.3× 18 0.3× 34 288
Wee Kheng Soo Australia 12 189 1.4× 133 1.3× 102 1.0× 31 0.6× 12 0.2× 23 600
Dario Pasalic United States 13 79 0.6× 37 0.4× 190 1.8× 26 0.5× 9 0.2× 30 412
Christopher J. Chow United States 8 169 1.3× 48 0.5× 55 0.5× 51 0.9× 5 0.1× 11 319

Countries citing papers authored by Noman Paracha

Since Specialization
Citations

This map shows the geographic impact of Noman Paracha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noman Paracha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noman Paracha more than expected).

Fields of papers citing papers by Noman Paracha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noman Paracha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noman Paracha. The network helps show where Noman Paracha may publish in the future.

Co-authorship network of co-authors of Noman Paracha

This figure shows the co-authorship network connecting the top 25 collaborators of Noman Paracha. A scholar is included among the top collaborators of Noman Paracha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noman Paracha. Noman Paracha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shore, Neal D., Amee Morgans, Martin Boegemann, et al.. (2025). Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis. European Journal of Cancer. 223. 115513–115513.
2.
3.
4.
Shore, Neal D., Alicia K. Morgans, Noman Paracha, et al.. (2024). A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?. Journal of Clinical Oncology. 42(4_suppl). 324–324.
5.
Partridge, Jamie, David Aceituno, Noman Paracha, & Howard Thom. (2023). A sequential therapy with sorafenib followed by regorafenib against single-line atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC): Indirect treatment comparisons (ITC) using the RESORCE study.. Journal of Clinical Oncology. 41(4_suppl). 537–537. 1 indexed citations
6.
Felizzi, Federico, et al.. (2022). P48 Joint Modelling Measurable Target Lesions, EQ5D/Utility and Overall Survival: Do We Still Need Partitioned Survival Models?. Value in Health. 25(1). S11–S11. 1 indexed citations
7.
Lo, Siu Hing, et al.. (2021). Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. PharmacoEconomics. 40(S1). 91–102. 7 indexed citations
8.
Briggs, Andrew, Alex Upton, Antoîne Italiano, et al.. (2021). Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study. Value in Health. 25(6). 1002–1009. 9 indexed citations
9.
Briggs, Andrew, Noman Paracha, Katherine L. Rosettie, et al.. (2021). Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study. Oncology. 100(2). 124–130. 1 indexed citations
10.
Felizzi, Federico, et al.. (2021). Mixture Cure Models in Oncology: A Tutorial and Practical Guidance. PharmacoEconomics - Open. 5(2). 143–155. 28 indexed citations
11.
Sutherland, C. Simone, Pollyanna Hudson, Stephen Mitchell, & Noman Paracha. (2021). Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers. PharmacoEconomics. 40(S1). 39–67. 10 indexed citations
12.
Paracha, Noman, Ksenija Gorni, & Pollyanna Hudson. (2020). PRO62 SPINAL MUSCULAR ATROPHY: DEVELOPMENT OF NATURAL HISTORY MODELS FOR DISEASE SUBTYPES. Value in Health. 23. S339–S339. 2 indexed citations
13.
Lo, Siu Hing, Noman Paracha, Ksenija Gorni, & Andrew Lloyd. (2020). PRO93 DO CAREGIVERS AND PATIENTS VALUE THE AVOIDANCE OF LUMBAR PUNCTURES IN SPINAL MUSCULAR ATROPHY? A STATED PREFERENCE SURVEY. Value in Health. 23. S346–S346. 2 indexed citations
14.
Conter, Henry Jacob, Scott Owen, Anna Zhou, et al.. (2019). Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC). Journal of Medical Economics. 22(7). 625–637. 25 indexed citations
15.
Paracha, Noman, et al.. (2018). Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients. Health and Quality of Life Outcomes. 16(1). 179–179. 45 indexed citations
16.
17.
Purchase, J. L., et al.. (2017). Health Related Quality of Life in Cancer Immunotherapy: Previously Treated, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Value in Health. 20(9). A450–A450. 1 indexed citations
18.
19.
Rochau, Ursula, et al.. (2014). Estimating Crossover Bias In A Randomized Clinical Trial Of Ovarian Cancer Treatment. Value in Health. 17(7). A564–A564. 1 indexed citations
20.
Woods, Beth, Noman Paracha, David A. Scott, & Nicholas Thatcher. (2011). Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer. 75(2). 261–267. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luc Ollivier Breakdown of academic impact, for papers by Diana Chirovsky Breakdown of academic impact, for papers by Chloe J. Bright Breakdown of academic impact, for papers by Yat Ming Lau Breakdown of academic impact, for papers by Laila A. Gharzai Breakdown of academic impact, for papers by John Waller Breakdown of academic impact, for papers by Kashyap Patel Breakdown of academic impact, for papers by Wee Kheng Soo Breakdown of academic impact, for papers by Dario Pasalic Breakdown of academic impact, for papers by Christopher J. Chow
Rankless by CCL
2026